panoptes-pharma.com
Uveitis | Panoptes
http://www.panoptes-pharma.com/pipeline/therapeutic_areas/uveitis
Business Model & Strategy. Key facts about Uveitis. Uveitis is one of the leading causes of blindness in the world and the fourth leading cause in the western world. Several million patients suffer from any form of uveitis. Posterior non-infectious uveitis is a registered orphan indication. Uveitis can occur in any age group. Current treatment involves corticosteroids (Prednisolon or Dexamethason) and severe immunosuppressive drugs (Cyclosporine). Business Model & Strategy.
panoptes-pharma.com
Business Model & Strategy | Panoptes
http://www.panoptes-pharma.com/company/business-model-strategy
Business Model & Strategy. Business Model & Strategy. Panoptes intends to develop PP-001 up to proof-of-concept studies in humans. For posterior uveitis, a sub-population of uveitis, orphan drug status will be applied which will allow accelerated approvals, financial incentives, higher reimbursement rates and prolonged market exclusivity. PANOPTES PHARMA GES.M.B.H, REISNERSTRASSE 34/1, 1030 WIEN, AUSTRIA. INFO@PANOPTES-PHARMA.COM. Business Model & Strategy.
panoptes-pharma.com
Management Team | Panoptes
http://www.panoptes-pharma.com/company/management-team
Business Model & Strategy. Franz Obermayr, Ph.D Chief Executive Officer. Stefan Sperl, Ph.D Chief Operating Officer. PANOPTES PHARMA GES.M.B.H, REISNERSTRASSE 34/1, 1030 WIEN, AUSTRIA. INFO@PANOPTES-PHARMA.COM. Business Model & Strategy.
panoptes-pharma.com
Company | Panoptes
http://www.panoptes-pharma.com/company
Business Model & Strategy. Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria. More information. We were inspired by Argus Panoptes, a giant in Greek mythology who possessed a hundred eyes. More information. Business Model and Strategy. Business Model & Strategy.
panoptes-pharma.com
Viral Conjunctivitis | Panoptes
http://www.panoptes-pharma.com/pipeline/therapeutic_areas/viral-conjunctivitis
Business Model & Strategy. Conjunctivitis (often called pink eye ) is an inflammation of the conjunctiva, which is the mucous membrane covering the white part of the eye and the inner side of the eyelid. Symptoms of EKC include acute onset of watering redness, foreign body sensation and severe pain, diminished eyesight, tearing, and sensitivity to light. In approximately 20-50% of patients, an immune T cell mediated infiltration of the corneal stroma that results in deteriorating vision is observed.
panoptes-pharma.com
About Us | Panoptes
http://www.panoptes-pharma.com/company/about-us
Business Model & Strategy. Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. Panoptes is located in the city center of Vienna, Austria. Panoptes’ aim is to generate future growth by achieving major development milestones and by entering into partnerships with leading pharmaceutical companies. We believe the combination of our technology and cost-efficient development strategy will he...
panoptes-pharma.com
News | Panoptes
http://www.panoptes-pharma.com/news
Business Model & Strategy. Ophthalmology company Panoptes Pharma successfully closed financing round. Press release 5: 11.02.2015. Panoptes will present at Bio Equity Europe. 19 20 May 2015, Vienna, Austria. More Information. Ophthalmology company Panoptes Pharma and Mediolanum announce License Agreement. Press release 4: 09.02.2015 Download Press Release. Panoptes participates at the BioEurope. 3 5 Nov. 2014, Frankfurt, Germany. www.ebdgroup.com/bioeurope. Panoptes presents at the OIS, Chicago.
panoptes-pharma.com
Further Indications | Panoptes
http://www.panoptes-pharma.com/pipeline/therapeutic_areas/further-indications-2
Business Model & Strategy. Based on the mode of action of PP-001 and its suitability for systemic and local administration a broad range of additional indications can be pursued. PANOPTES PHARMA GES.M.B.H, REISNERSTRASSE 34/1, 1030 WIEN, AUSTRIA. INFO@PANOPTES-PHARMA.COM. Business Model & Strategy.
panoptes-pharma.com
Partners | Panoptes
http://www.panoptes-pharma.com/partner
Business Model & Strategy. Austrian Research Promotion Agency FFG. Panoptes’ development program is funded by the. Austrian Research Promotion Agency FFG. Panoptes Pharma is funded by LISA Seedfinancing administered by aws on behalf of the Austrian Ministry of Economy, Family and Youth (BMWFJ). PANOPTES PHARMA GES.M.B.H, REISNERSTRASSE 34/1, 1030 WIEN, AUSTRIA. INFO@PANOPTES-PHARMA.COM. Business Model & Strategy.
